Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 11.93
- Piotroski Score 3.00
- Grade Buy
- Symbol (MREO)
- Company Mereo BioPharma Group plc
- Price $3.58
- Changes Percentage (2.52%)
- Change $0.09
- Day Low $3.40
- Day High $3.59
- Year High $5.02
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $7.50
- High Stock Price Target $8.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.15
- Trailing P/E Ratio -22.8
- Forward P/E Ratio -22.8
- P/E Growth -22.8
- Net Income $-29,466,000
Income Statement
Quarterly
Annual
Latest News of MREO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
MREO Stock Price | Mereo BioPharma Group PLC ADR Stock Quote (U.S.: Nasdaq) | MarketWatch
Mereo BioPharma Group Plc is a biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. Founded in 2015 in London, they have a portfolio of innovat...
By MarketWatch | 5 months ago
